KRAS and colorectal cancer: For example, Xu et al. 51 showed that enhanced RAD21 expression confers poor prognosis and drug resistance in high grade luminal, basal and HER2+ breast cancers, while Deb and colleagues52 showed that RAD21 overexpression is predictive of poor prognosis in KRAS mutant colorectal cancers.